Strong demand for glucagon-like peptide 1 (GLP-1) agonists for weight loss and diabetes is a leading reason for CordenPharma to ramp up its peptide services, CEO Michael Quirmbach says.

CordenPharma will provide 100 million autoinjectors, 100 million vial and syringe products, and over 1 billion oral VK2735 tablets annually through dedicated manufacturing lines. In addition, VKTX ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

Viking signs a long-term manufacturing agreement with CordenPharma Viking announced a long-term partnership to support the potential commercial demand for VK2735 with CordenPharma. According to ...

BASEL, Switzerland, March 5, 2025 /PRNewswire/ -- Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral ...